KALOBIOS PHARMACEUTICALS INC Form SC 13G February 13, 2013

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## **SCHEDULE 13G**

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(AMENDMENT NO. )\*

# KALOBIOS PHARMACEUTICALS, INC.

(Name of Issuer)

Common stock

(Title of Class of Securities)

48344T100

(CUSIP Number)

December 31, 2012

(Date of Event Which Requires Filing of this Statement)

### Edgar Filing: KALOBIOS PHARMACEUTICALS INC - Form SC 13G

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:			
"Rule 13d-1(b)			
"Rule 13d-1(c)			
x Rule 13d-1(d)			

<sup>\*</sup> The remainder of this cover page shall be filled out for a reporting person s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 2 of 5 Pages

1.	NAMES OF	REPORTING PERSONS
	I.R.S. IDENT	TIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
2.		ational Inc. 36-0781620 E APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
	(a) "	
3.	(b) " SEC USE ON	NLY
4.	CITIZENSHI	IP OR PLACE OF ORGANIZATION
	Delaware 5.	SOLE VOTING POWER
NUMB	ER OF	
SHA		3,000,308* SHARED VOTING POWER
BENEFICIALLY		
OWNE	7.	0 SOLE DISPOSITIVE POWER
REPORTING		
PERS WI	8.	3,000,308* SHARED DISPOSITIVE POWER
9.		0 TE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
10.	3,000,308* CHECK IF T	THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

### Edgar Filing: KALOBIOS PHARMACEUTICALS INC - Form SC 13G

11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9	"

27.99%\*\*

12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

CO

- \* Does not give effect to a reverse stock split of the issuer s issued and outstanding capital stock which became effective on January 15, 2013. See Item 4.
- \*\* Percentage of class calculation is based upon the number of shares of issuer s common stock outstanding as disclosed in issuer s Form 10-Q for the period ended September 30, 2012 and does not give effect to a reverse stock split of the issuer s issued and outstanding capital stock which became effective on January 15, 2013. See Item 4.

Page 3 of 5 Pages

Item 1. (a) Name of Issuer: KaloBios Pharmaceuticals, Inc.		
(b) <u>Address of Issuer s Principal Executive Offices:</u> 260 East Grand Ave., South San Francisco, CA 94080		
Item 2. (a) Name of Person Filing: Baxter International Inc.		
(b) Address of Principal Office or, if none, Residence: One Baxter Parkway, Deerfield, Illinois 60015-4625		
(c) <u>Citizenship or Place of Organization</u> : Delaware		
(d) <u>Title of Class of Securities</u> : Common stock		
(e) <u>CUSIP Number</u> : 48344T100  Item 3. If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):		
(a) "Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);		
(b) "Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);		
(c) "Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);		
(d) "Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);		
(e) "Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);		
(f) "Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);		
(g) "Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G):		

Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

Company Act of 1940 (15 U.S.C. 80a-3)

Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment

(h)

(i)

### Edgar Filing: KALOBIOS PHARMACEUTICALS INC - Form SC 13G

(j) Group, in accordance with Section 240.13d-1(b)(1)(ii)(J). **Item 4.** Ownership.

Amount beneficially owned: 3,000,308\*

(a)

\* Does not give effect to a reverse stock split of the issuer s issued and outstanding capital stock which became effective on January 15, 2013.

Page 4 of 5 Pages

	(b)	Percer	nt of class: 27.99%**		
**	Percentage of class calculation is based upon the number of shares of issuer s common stock outstanding as disclosed in issuer s Form 10-Q for the period ended September 30, 2012 and does not give effect to a reverse stock split of the issuer s issued and outstanding capital stock which became effective on January 15, 2013.				
	(c)	Numb	per of shares as to which the person has:		
		(i)	Sole power to vote or to direct the vote: 3,000,308*		
		(ii)	Shared power to vote or to direct the vote: 0		
		(iii)	Sole power to dispose or to direct the disposition of: 3,000,308*		
		(iv)	Shared power to dispose or to direct the disposition of: 0		
into	2013 f Dec shares	3. ember 3 s of issu	ve effect to a reverse stock split of the issuer s issued and outstanding capital stock which became effective on January 15, 31, 2012, the reporting person owned 3,000,308 shares of issuer s Series D Preferred Stock, convertible on a one-to-one basis are s common stock. In accordance with Rule 13d-3, the reporting person s percentage ownership is calculated on the assumption res of issuer s convertible preferred stock are converted into common stock.		
Item	5. <u>O</u>	wnershi	ip of Five Percent or Less of a Class.		
			s being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than e class of securities, check the following ".		
Item	6. <u>O</u>	wnershi	ip of More Than Five Percent on Behalf of Another Person.		
N/A					
Item N/A	17. <u>I</u> c	dentifica	ation and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:		
Item	8. <u>Id</u>	lentifica	ation and Classification of Members of the Group.		
N/A					
Item	9. <u>N</u>	otice of	Dissolution of Group.		
N/Δ					

Item 10. Certification:

N/A

Page 5 of 5 Pages

#### **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 13, 2013

#### BAXTER INTERNATIONAL INC.

By: /s/ Stephanie A. Shinn
Name: Stephanie A. Shinn
Title: Corporate Vice President,
Associate General Counsel and
Corporate Secretary